NICE recommends Taltz (ixekizumab)from Eli Lilly to treatsevere plaque psoriasis.
The National Institute for Health and Care Excellence (NICE) has published draft guidelines recommending use of Taltz (ixekizumab)from Eli Lilly for severe plaque psoriasis, as per a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10, and where the patient has not responded to standard systemic therapies or patients are unable to take them.
The recommendation is conditional on the continued provision of a Patient Access Scheme, under which Taltz (ixekizumab) is offered at a confidential discount to the NHS, and stipulates that treatment is stopped at 12 weeks if psoriasis has not responded adequate.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.